Perry David P's Form 4 filing
Better Therapeutics, Inc.BTTX · filed Nov 1, 2021
- Accession no.
- 0000899243-21-042250
- Filed
- Nov 1, 2021, 8:55 PM ET
- Trade date
- Apr 30-Oct 28, 2021
- Filing delay
- 185 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 12 non-derivative transactions and 1 derivative transaction. Open-market purchases total $2.51M. It was filed 185 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Perry David PCIK 0001105941 | Director, Officer (See Remarks), 10% Owner |
| David P. Perry 2015 TrustCIK 0001890678 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 30, 2021 | Common Stock | PPurchaseAcquired | +2,000 | $9.95 | +$19,900 | 2,000 | Direct | |
| May 4, 2021 | Common Stock | PPurchaseAcquired | +3,476 | $9.93 | +$34,516.68 | 5,476 | Direct | |
| May 13, 2021 | Common Stock | PPurchaseAcquired | +7,000 | $9.93 | +$69,510 | 12,476 | Direct | |
| May 14, 2021 | Common Stock | PPurchaseAcquired | +3,060 | $9.93 | +$30,385.8 | 15,536 | Direct | |
| May 21, 2021 | Common Stock | PPurchaseAcquired | +8,000 | $9.95 | +$79,600 | 23,536 | Direct | |
| May 24, 2021 | Common Stock | PPurchaseAcquired | +8,000 | $9.94 | +$79,520 | 31,536 | Direct | |
| May 26, 2021 | Common Stock | PPurchaseAcquired | +20,000 | $9.95 | +$199,000 | 51,536 | Direct | |
| Oct 28, 2021 | Common Stock | AGrant or awardAcquired | +10,164,015 | –F3,F4 | – | 10,215,551 | Indirect | |
| Oct 28, 2021 | Common Stock | AGrant or awardAcquired | +293,150 | –F3,F4 | – | 10,508,701 | Indirect | |
| Oct 28, 2021 | Common Stock | AGrant or awardAcquired | +21,336 | –F3,F4 | – | 10,530,037 | Indirect | |
| Oct 28, 2021 | Common Stock | PPurchaseAcquired | +200,000 | $10.00 | +$2,000,000 | 10,730,037 | Indirect | |
| Oct 28, 2021 | Common Stock | AGrant or awardAcquired | +100,000 | $10.00 | +$1,000,000 | 10,830,037 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 28, 2021 | Common Stock | AGrant or awardAcquired | +28,300 | $0.00 | $0 | 28,300 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Pursuant to the Agreement and Plan of Merger, dated April 6, 2021, as amended (the "Merger Agreement"), by and among Mountain Crest Acquisition Corp. II ("Issuer"), MCAD Merger Sub Inc. ("Merger Sub") and Better Therapeutics, Inc. ("BTX"), on October 28, 2021, Merger Sub merged with and into BTX, with BTX surviving the merger as a wholly-owned subsidiary of Issuer (such merger and the other transactions contemplated by the Merger Agreement, the "Business Combination").
Referenced by the price of 3 transactions in Table I.
- F4
At the effective time of the Business Combination (the "Effective Time"), each share of BTX common stock (including shares of BTX common stock resulting from the conversion of BTX preferred stock and BTX Simple Agreements for Future Equity) was converted into a right to receive the number of shares of Issuer common stock equal to the product of the number of shares of BTX common stock and 0.9475 (the "Exchange Ratio"), with fractional shares rounded to the nearest whole share. Issuer subsequently changed its name to Better Therapeutics, Inc.
Referenced by the price of 3 transactions in Table I.
Remarks
Executive Chairman of the Board of Directors